IL306046A - A preparation for use in the treatment of disorders related to MHC-1 - Google Patents
A preparation for use in the treatment of disorders related to MHC-1Info
- Publication number
- IL306046A IL306046A IL306046A IL30604623A IL306046A IL 306046 A IL306046 A IL 306046A IL 306046 A IL306046 A IL 306046A IL 30604623 A IL30604623 A IL 30604623A IL 306046 A IL306046 A IL 306046A
- Authority
- IL
- Israel
- Prior art keywords
- opathies
- composition
- mhc
- treating
- treating mhc
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/485—Exopeptidases (3.4.11-3.4.19)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163171672P | 2021-04-07 | 2021-04-07 | |
| PCT/US2022/023685 WO2022216832A1 (en) | 2021-04-07 | 2022-04-06 | A composition for use in treating mhc-1-opathies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL306046A true IL306046A (en) | 2023-11-01 |
Family
ID=81580496
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL306046A IL306046A (en) | 2021-04-07 | 2022-04-06 | A preparation for use in the treatment of disorders related to MHC-1 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US12370257B2 (https=) |
| EP (1) | EP4320166A1 (https=) |
| JP (1) | JP2024515240A (https=) |
| KR (1) | KR20230167355A (https=) |
| CN (1) | CN117321084A (https=) |
| AU (1) | AU2022256043A1 (https=) |
| CA (1) | CA3215902A1 (https=) |
| IL (1) | IL306046A (https=) |
| MX (1) | MX2023011720A (https=) |
| WO (1) | WO2022216832A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL248777B1 (pl) * | 2024-03-05 | 2026-01-26 | Inst Immunologii I Terapii Doswiadczalnej Im Ludwika Hirszfelda Polskiej Akademii Nauk | Sposób określania ciężkości reumatoidalnego zapalenia stawów na podstawie pomiaru stężenia białka ERAP2 |
| CN118047824B (zh) * | 2024-04-01 | 2024-06-28 | 北京瑞博奥医药科技有限公司 | 二烷基膦酸在寡核苷酸合成中的应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2804763C (en) | 2010-07-14 | 2023-01-03 | The Regents Of The University Of California | Biomarkers for diagnosis of transient ischemic attacks |
| US20130315933A1 (en) | 2010-10-06 | 2013-11-28 | Christoph Renner | Antibodies Directed Against HLA-B27 Homodimers and Methods and Uses Thereof in Diagnosis and Therapy |
| US8969254B2 (en) | 2010-12-16 | 2015-03-03 | Dana-Farber Cancer Institute, Inc. | Oligonucleotide array for tissue typing |
| TWI619729B (zh) | 2012-04-02 | 2018-04-01 | 再生元醫藥公司 | 抗－ｈｌａ－ｂ*２７抗體及其用途 |
| WO2013162368A1 (en) | 2012-04-26 | 2013-10-31 | Stichting Vu-Vumc | Biomarkers |
| HK1213830A1 (zh) | 2012-10-10 | 2016-07-15 | Teva Pharmaceutical Industries Ltd. | 用於预测醋酸格拉替雷临床反应的生物标志物 |
| KR101748867B1 (ko) | 2013-04-19 | 2017-06-20 | 주식회사 젠큐릭스 | 조기 유방암 예후 예측 진단용 자동화 시스템 |
| US20160145687A1 (en) | 2013-06-25 | 2016-05-26 | Turun Yliopisto | Method of Predicting Risk for Type 1 Diabetes |
| US9907833B2 (en) | 2013-07-25 | 2018-03-06 | University Of Florida Research Foundation, Incorporated | Use of relaxin to treat placental syndromes |
| US10927412B2 (en) | 2013-10-01 | 2021-02-23 | The Regents Of The University Of California | Endometriosis classifier |
| US10166210B2 (en) | 2014-06-12 | 2019-01-01 | Nsabp Foundation, Inc. | Methods of subtyping CRC and their association with treatment of colon cancer patients with oxaliplatin |
| EP3730188B1 (en) | 2015-08-21 | 2024-07-31 | The Children's Hospital of Philadelphia | Compositions and methods for use in combination for the treatment and diagnosis of autoimmune diseases |
| WO2017191274A2 (en) | 2016-05-04 | 2017-11-09 | Curevac Ag | Rna encoding a therapeutic protein |
| GB201609712D0 (en) | 2016-06-03 | 2016-07-20 | Babraham Inst | Disease targets and biomarkers |
| US20190375842A1 (en) | 2018-01-04 | 2019-12-12 | Vanderbilt University | Check point inhibition in organ fibrosis |
| WO2019140380A1 (en) | 2018-01-12 | 2019-07-18 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| US11632728B2 (en) | 2019-07-18 | 2023-04-18 | Qualcomm Incorporated | Directional measurements for sidelink synchronization signal transmission |
| US12195723B2 (en) | 2019-11-08 | 2025-01-14 | The Broad Institute, Inc. | Engineered antigen presenting cells and uses thereof |
| WO2021113805A1 (en) | 2019-12-05 | 2021-06-10 | The General Hospital Corporation | Multi-biomarker prediction models for multiple infection episodes following blunt trauma |
-
2022
- 2022-04-06 JP JP2023561645A patent/JP2024515240A/ja active Pending
- 2022-04-06 WO PCT/US2022/023685 patent/WO2022216832A1/en not_active Ceased
- 2022-04-06 KR KR1020237032803A patent/KR20230167355A/ko active Pending
- 2022-04-06 AU AU2022256043A patent/AU2022256043A1/en active Pending
- 2022-04-06 IL IL306046A patent/IL306046A/en unknown
- 2022-04-06 EP EP22721534.0A patent/EP4320166A1/en active Pending
- 2022-04-06 US US17/714,717 patent/US12370257B2/en active Active
- 2022-04-06 CA CA3215902A patent/CA3215902A1/en active Pending
- 2022-04-06 CN CN202280026149.XA patent/CN117321084A/zh active Pending
- 2022-04-06 MX MX2023011720A patent/MX2023011720A/es unknown
-
2025
- 2025-06-25 US US19/249,070 patent/US20250375519A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023011720A (es) | 2023-10-12 |
| US20220323581A1 (en) | 2022-10-13 |
| US12370257B2 (en) | 2025-07-29 |
| KR20230167355A (ko) | 2023-12-08 |
| CN117321084A (zh) | 2023-12-29 |
| EP4320166A1 (en) | 2024-02-14 |
| AU2022256043A1 (en) | 2023-10-12 |
| AU2022256043A9 (en) | 2023-10-26 |
| WO2022216832A1 (en) | 2022-10-13 |
| JP2024515240A (ja) | 2024-04-08 |
| US20250375519A1 (en) | 2025-12-11 |
| CA3215902A1 (en) | 2022-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202104356VA (en) | Bt1718 for use in treating cancer | |
| IL290996A (en) | Neurotoxin preparations for headache treatment | |
| SMT202400216T1 (it) | Inibitore di IRAK4 in combinazione con un inibitore di BCL-2 per l’uso nel trattamento di un cancro | |
| IL277629A (en) | RET inhibitor for use in the treatment of cancer involving a change in RET | |
| PL4076461T3 (pl) | Lumateperon do stosowania w leczeniu schizofrenii | |
| IL306046A (en) | A preparation for use in the treatment of disorders related to MHC-1 | |
| ZA202007955B (en) | Ccr5 inhibitor for use in treating cancer | |
| IL286949A (en) | Mesitantan for use in the treatment of portopulmonary hypertension | |
| PT4313058T (pt) | Composição que compreende roginolisib e regime de dosagem para tratar cancro ou uma doença inflamatória ou autoimune | |
| GB2595089B (en) | Compositions for use in methods for preventing or treating incontinence, overactive bladder, or menstrual cramping | |
| HK40106248A (en) | A composition for use in treating mhc-1-opathies | |
| ZA202202571B (en) | Neurotoxin compositions for use in treating gastroparesis | |
| GB201912159D0 (en) | A composition for use in treating fibromyalgia | |
| GB201611365D0 (en) | A composition for use in treating rotavirus infection | |
| ES3063612T3 (en) | Machine for use in civil engineering | |
| HK40088956A (en) | A composition comprising hp-hmg for use in treating infertility | |
| PL4157247T3 (pl) | Cysteamina do zastosowania w terapii przeciwwirusowej | |
| GB202107487D0 (en) | Composition for treating a keratinous surface | |
| GB201918539D0 (en) | Compounds for use in treatment and prophylaxis | |
| HK40077524A (en) | Tak-925 for use in treating narcolepsy | |
| GB202019762D0 (en) | Compounds for use in treatment and prophylaxis | |
| GB202006685D0 (en) | A composition for anti-mircobial use | |
| GB2560769B (en) | Compounds and compositions for use in treating psoriasis | |
| GB202306057D0 (en) | A composition for anti-microbial use | |
| PL4203959T3 (pl) | Kompozycja zawierająca tTF-NGR do zastosowania w leczeniu mięsaka tkanek miękkich |